Ocean Ring Technologies Competitors

We are the world’s leading Geo-data specialist, collecting and analysing comprehensive information about the Earth and the structures built upon it. Through integrated data acquisition, analysis and advice, we unlock insights from Geo-data to help our clients design, build and operate their assets in a safe, sustainable and efficient manner. Learn more about us: https://www.youtube.com/fugro https://www.facebook.com/fugro https://twitter.com/fugro https://www.instagram.com/fugro/

Our story began more than 40 years ago. Today we are a global company, among the largest players in the energy sector in Europe and the 4th largest producer of wind energy. We are proud to be a leading utility integrated in the Dow Jones Sustainability Indexes (World). We want to build a new energy by promoting renewable sources. To do this, we have chosen ... ... to be 100% green by 2030; ... to be Net Zero by 2040; ... to innovate, to shape the energy sector; ... empower our communities to live more sustainably. Ours is the energy that strives to create a better future, inspired by people from four regional hubs. It is the energy that knows no borders, that never sleeps, and that connects us to you. We will harness wind, sun and water to lead the energy transition. We will all be green. We choose the Earth. Welcome to the official EDP Group LinkedIn page.

Targeting Cancer. Transforming Therapies. Seagen is where revolutionary science meets transformative cancer therapy. Seagen is committed to advancing late-stage clinical trials and expanding the development of its portfolio both in and outside the U.S. to better the health of people with cancer. We are dedicated to improving patient outcomes through advanced antibody-drug conjugate technology designed to deliver cell-killing agents directly to tumor cells. We are focused on discovering, developing and commercializing a new generation of transformative cancer medicines and empowered antibody-based therapies that have the potential to change the foundation of treatment for people with cancer. Our industry-leading antibody-drug conjugate (ADC) technology combines the specificity of monoclonal antibodies, innovative linker systems, and the power of potent cell-killing agents to treat cancer. Using our proprietary technology, we are able to optimize each ADC to potentially improve outcomes for patients. ADCs are an integral part of the evolving cancer treatment paradigm with their specificity, stability and potency. We are expanding indications for three already approved cancer medicines and a pipeline of more than five novel targeted therapies at various stages of preclinical and clinical testing designed to address significant unmet medical needs.